Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Return on Invested Capital (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Return on Invested Capital for 15 consecutive years, with 0.03% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital fell 1.0% to 0.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.03% through Dec 2025, down 1.0% year-over-year, with the annual reading at 0.03% for FY2025, 1.0% down from the prior year.
  • Return on Invested Capital hit 0.03% in Q4 2025 for Ligand Pharmaceuticals, up from 0.02% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.14% in Q2 2021 to a low of 0.06% in Q1 2025.
  • Historically, Return on Invested Capital has averaged 0.03% across 5 years, with a median of 0.01% in 2023.
  • Biggest YoY gain for Return on Invested Capital was 15bps in 2021; the steepest drop was -23bps in 2021.
  • Year by year, Return on Invested Capital stood at 0.13% in 2021, then plummeted by -100bps to 0.0% in 2022, then skyrocketed by 2598bps to 0.01% in 2023, then soared by 194bps to 0.04% in 2024, then fell by -25bps to 0.03% in 2025.
  • Business Quant data shows Return on Invested Capital for LGNDZ at 0.03% in Q4 2025, 0.02% in Q3 2025, and 0.04% in Q2 2025.